FindTrial
Sign In

The role of saroglitazar in the treatment of prediabetes and elevated lipid levels

Study of saroglitazar in treatment of prediabetes with dyslipidemia - STOP-D

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/03/006778
Enrollment
40
Registered
2016-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Prediabetes with dyslipidemia

Interventions

Intervention1: Saroglitazar: 4 mg
Route - oral
Tabletl once daily
for 24 weeks

Sponsors

Deogiri Diabetes Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Willing to participate in the study and follow protocol. Patients of either sex with age group of 20-60 years. Prediabetic patients with HbA1c 5.7- 6.5 % and deranged lipids as per NCEP guidelines.

Exclusion criteria

Exclusion criteria: Type 1 diabetes mellitus Type 2 diabetes Secondary hypertension. Bronchial asthma. Chronic obstructive pulmonary disease. Any other respiratory disorders. g. Any Hepatic or renal diseases. h. Any other cardiovascular disorder. ï?? Pregnant and lactating women. ï?? History of known allergy to drugs. ï?? Patient concurrently taking other medication which is known to affect the blood sugar and lipid parameters. ï?? Smoker, alcoholic and tobacco chewer.

Design outcomes

Primary

MeasureTime frame
Change in serum triglyceridesTimepoint: 24 weeks—

Secondary

MeasureTime frame
change in HbA1c, total cholesterol, LDL-C, VLDL-C, non HDL-C, HDL-CTimepoint: week 24—

Countries

India

Contacts

Public ContactDr Deepak Bhosle

Deogiri Diabetes Centre

drdeepakbhosle@gmail.com7770087870

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026